Alzamend Neuro announced receipt of a “Study May Proceed” letter from the FDA for the initiation of study AL001-BD01, a Phase IIA clinical study of AL001 for BD type 1.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALZN:
